SCHEMBL1752202

SCHEMBL1752202

COC(=O)c1ccc(-c2cc(Cl)c(CN3CCC4(CCC(O[Si](c5ccccc5)(c5ccccc5)C(C)(C)C)CC4)C3=O)c(Cl)c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.39
CHRM4 P08173 1/20 0.38
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
ABL1 P00519 1/20 0.34
HDAC11 Q96DB2 1/20 0.34
POLB P06746 1/20 0.33
KDM1A O60341 1/20 0.33
MAOB P27338 1/20 0.33
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1750496 0.93 BACE1 (0.40) BACE1HDAC11RIPK1
SCHEMBL1750080 0.88 BACE1 (0.41) BACE1HCRTR1HCRTR2HDAC11RIPK1
SCHEMBL1751913 0.86 RIPK1 (0.39) BACE1LMNARIPK1
SCHEMBL1750366 0.85 BACE1 (0.40) BACE1HCRTR1HCRTR2HDAC11PDE4A
SCHEMBL2301573 0.84 CHRM4 (0.37) BACE1CHRM4ALDH1A1SMN1; SMN2HTT
SCHEMBL12386297 0.84 TNKS (0.39) CHRM4
SCHEMBL1750955 0.81 BACE1 (0.38) BACE1HCRTR1HCRTR2NPC1RAB9A
SCHEMBL1751025 0.80 NPC1 (0.46) CHRM4HCRTR1HCRTR2HDAC11POLB
SCHEMBL1750766 0.79 BACE1 (0.37) BACE1HCRTR1HCRTR2HDAC11RIPK1
SCHEMBL1752204 0.78 CHRM4 (0.37) BACE1CHRM4ABL1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968585-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2011-06-28 US disclosed
EP-2035379-B1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2010-06-16 EP disclosed
US-20090099180-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-16 US disclosed
EP-2035379-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 Eli Lilly & Company (US) 2009-03-18 EP disclosed
WO-2007127763-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099180-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD11B2, HSD3B1 BACE1 155/4885CHRM4 4658/4885HCRTR1 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.